Search this site

Split Cord Malformation Q. What is a split cord malformation? A split cord malformation is a congenital spinal dysraphism in which the spinal cord is longitudinally divided into two hemicords, each containing its own dorsal and ventral nerve roots and central canal. The split is produced by a persistent abnormal midline tract composed of mesenchymal, endodermal, or ectodermal tissue, which physically divides the neural tube. SCM is strongly associated with tethered cord syndrome and progressive neurological deterioration. Q. How are split cord malformations classified? SCM is divided into two main types: Type I SCM: The hemicords lie in separate dural sacs, separated by a rigid osseocartilaginous septum. The septum is typically anchored to the vertebral body and creates fixed tethering. Type II SCM: Both hemicords lie in a single dural sac, separated by a non-rigid fibrous septum. The tethering effect is generally less severe than in Type I. Type I tends to cause earlier and more significant symptoms because the bony spur acts as a fixed mechanical tether. Q. What is the embryological basis of split cord malformations? SCM arises from formation of an accessory neurenteric canal early in development. This abnormal tract allows ectoderm, mesoderm, and endoderm to mix. Mesenchyme condenses along this tract, forming a persistent midline structure that differentiates into either bone/cartilage (Type I) or fibrous tissue (Type II). If the abnormal tract splits the forming dura early, two dural sacs develop; if late or incomplete, a single sac remains. Q. Why is scoliosis common in SCM? Scoliosis develops due to chronic asymmetrical tethering forces acting on the hemicords. The distorted pull on the neuroaxis during growth produces progressive curve formation. Scoliosis may be the presenting feature and should always prompt MRI evaluation for SCM. Q. What are the indications for surgery in SCM? Surgery is indicated for: Progressive neurological deficits Orthopedic deformity progression (scoliosis, foot deformity) Urological deterioration Presence of a rigid midline septum producing fixed tethering Associated lesions with high risk, such as dermal sinus tract Symptomatic tethered cord regardless of type Type I SCM is generally treated earlier because the rigid septum always produces tethering. Q. What is diastematomyelia? Diastematomyelia is the classical form of Type I Split Cord Malformation, in which the spinal cord is divided into two hemicords by a rigid osseous or cartilaginous septum. The two hemicords lie in separate dural tubes. The septum is usually anchored to the vertebral body, producing a fixed tethering effect. Q. What is the embryological mechanism behind diastematomyelia? It results from early formation of an accessory neurenteric canal, allowing mesenchymal tissue to migrate into the midline and form an osseocartilaginous spur. Because this occurs early in dural development, the dura splits into two separate sacs. Q. What clinical features suggest diastematomyelia? Children usually present with: Progressive scoliosis Neurological deterioration: weakness, gait abnormalities Sensory deficits Foot deformities (cavovarus, clubfoot) Orthopedic asymmetry (limb-length difference) Urological dysfunction Skin findings such as hairy patches, dermal sinuses, lipomas, dimples, or angiomas frequently overly the defect. Q. What imaging features characterize diastematomyelia? MRI shows two hemicords in separate dural sacs with a midline septum. CT is essential for defining the bony spur. Often associated with vertebral anomalies including hemivertebra or block vertebra. Q. What complications are seen in diastematomyelia surgery? Risks include neural injury, root damage, CSF leak, pseudomeningocele, infection, residual septum causing retethering, and postoperative deformity progression. Q. What is the prognosis for diastematomyelia? Early surgery before severe neurological decline provides the best outcomes. Type I SCMs have a higher retethering risk due to the rigid spur and separate dural sacs. Q. What is diplomyelia? Diplomyelia is a true duplication of the spinal cord, where two complete spinal cords exist side-by-side, each surrounded by its own pia and typically enclosed in a single dural sac. Unlike diastematomyelia, there is no bony or fibrous septum splitting the canal. Q. How is diplomyelia different from diastematomyelia? Diplomyelia: true duplication of the spinal cord, two cords develop independently, usually in a single dural sac, no septum. Diastematomyelia: one cord split into two hemicords by a septum with two dural sacs (Type I SCM). Diplomyelia is extremely rare compared to diastematomyelia. Q. What is the embryological basis of diplomyelia? It likely results from complete duplication of the notochord or neural plate during early gastrulation, unlike SCM Type I which stems from an accessory neurenteric canal and septum formation. Q. How does diplomyelia present clinically? Symptoms resemble tethered cord: gait disturbance, weakness, sensory changes, scoliosis, orthopedic deformities, and bladder dysfunction. Skin markers may be present but are less consistent than in diastematomyelia. Q. What does MRI show in diplomyelia? MRI shows two fully formed cords without a septum and usually within one dural sac. No bony spur is seen. Associated anomalies may include tethered cord, dermoid, lipoma, or segmentation abnormalities. Q. How is diplomyelia treated? Surgery aims to de-tether the cord, release any adhesions, and perform duraplasty. Because there is no bony spur to remove, surgery focuses on freeing the cords from tethering bands and reconstructing a capacious dural sac. Care must be taken not to confuse duplicated cords with roots or placode. Q. What is the prognosis of diplomyelia? Generally depends on associated anomalies and extent of tethering. Outcomes are better than in diastematomyelia because no rigid septum is present. Long-term follow-up is essential due to risk of retethering. Surgical Steps for Split Cord Malformation: I will position the child prone with careful padding of all pressure points and mark the midline over the suspected split cord level. After a wide antiseptic preparation and draping, I will make a midline incision and expose the posterior elements of the spine. I will perform a laminectomy or laminotomy spanning the entire cranio-caudal extent of the split so that both the septum and both hemicords are fully accessible. I will remove only the minimum bone needed to avoid postoperative instability while still ensuring complete visualization of the midline spur and the dural sleeves. Under the operating microscope, I will open the dura longitudinally. In Type I split cord malformation, I will encounter two separate dural sacs, each containing a hemicord. I will open each dural tube along its length and tack the margins laterally to maintain exposure. I will then identify the rigid osseous or cartilaginous septum that divides the canal. This septum is often attached deeply to the posterior vertebral body, so I will carefully dissect around it circumferentially to define its margins. Using a high-speed drill, fine osteotomes, or micro-rongeurs, I will remove the septum completely from dorsal to ventral, ensuring that the entire bony anchor at its base is eliminated. I will work slowly and precisely to avoid injury to the hemicords and their exiting roots, which may course very close to the septum. In Type II split cord malformation, I will find both hemicords within a single dural sac, separated by a fibrous band. In this situation, I will sharply dissect the fibrous septum away from the neural tissue, cutting it completely to release the abnormal tethering connection. I will also look for additional tethering structures such as arachnoidal adhesions, fibrofatty bands, or thickened filum components, and I will divide these carefully to ensure the hemicords are entirely free. After removing the septum in Type I or releasing the fibrous band in Type II, I will inspect the conus and both hemicords to ensure they move freely without fixed points. I will then create a single, capacious dural sac for both hemicords. In Type I, this requires unifying the two dural sleeves by incising their medial walls and reconstructing one large dural space. I will perform a generous duraplasty using autologous fascia or a synthetic graft to prevent postoperative retethering and to allow the neural elements enough room for physiological movement. I will close the dura in a watertight fashion with fine sutures, ensuring no leaks or tension points remain. Once the dura is closed, I will close muscle, fascia, subcutaneous tissue, and skin in layered fashion, taking care to avoid tension that might compromise wound healing. I will maintain meticulous hemostasis and confirm that the reconstructed canal has no compressive elements remaining. Postoperatively, I will monitor neurological function, bladder status, and wound integrity, and arrange follow-up imaging to assess the adequacy of detethering and exclude retethering or postoperative complications.

Explore specialized neurosurgical modules designed for case-based mastery. Cranial View Module Spinal View Module Anatomy View Module Vascular View Module Neuroimaging View Module TNCR Review Notes View Module

Announcing Soon.

Myeloschisis Myeloschisis is the most severe form of open spinal dysraphism, where the neural tube fails to close completely, resulting in a flat, open neural plate that lies flush with the skin surface without a sac, meninges, or skin covering. It represents complete failure of primary neurulation. Q. How does myeloschisis differ from myelomeningocele? In myelomeningocele, the neural placode protrudes outward and may form a sac; in myeloschisis, the placode is completely flat and level with the skin, with no CSF-filled sac and no meningeal expansion. Myeloschisis indicates a more profound neurulation failure and generally has more severe neurological deficits. Q. What is the embryological basis of myeloschisis? Myeloschisis results from a complete failure of primary neurulation, specifically the failure of the neural folds to elevate and fuse in the midline between gestational days 22 and 28. The sequence of embryological events includes: Failure of Neural Fold Fusion: The primitive neuroectoderm fails to invaginate and remains exposed as a flat, un-closed neural plate (placode). Failure of Dysjunction: Because fusion never occurs, the surface ectoderm fails to separate from the neuroectoderm. Blockade of Mesodermal Migration: The persistent connection between surface ectoderm and neural tissue prevents paraxial mesenchyme from migrating into the dorsal midline. Absence of Dorsal Elements: Lacking mesodermal investment, there is subsequent failure of formation of the dura mater, paraspinal muscles, posterior bony arches (spina bifida), and overlying dermis. Consequently, the neural placode lies completely exposed on the infant's back, continuous at its lateral margins with the surrounding skin, and subject to secondary in utero chemical damage from amniotic fluid exposure. Q. What are the clinical features of myeloschisis? Infants present with a wide, open, flat placode at birth, typically in the lumbar or lumbosacral region. Neurological deficits are severe and correspond to the lesion level, including complete motor and sensory loss below the defect, neurogenic bladder, and lower limb deformities. There is near-universal association with Chiari II malformation, hydrocephalus, and brainstem abnormalities. Q. How is myeloschisis diagnosed? Diagnosis is clinical at birth: a flat, exposed neural plate without skin or sac. MRI is later performed to evaluate Chiari II, hydrocephalus, and associated anomalies. Antenatal ultrasound and fetal MRI can detect the open defect, ventriculomegaly, and hindbrain changes. Q. How will you manage a newborn with myeloschisis? Management parallels myelomeningocele: immediate sterile dressing, prone positioning, antibiotics if indicated, and urgent closure within 24–48 hours. The goal is to prevent infection and protect the neural tissue, though neurological deficits are typically fixed. Concurrent evaluation for hydrocephalus and Chiari II is essential. Q. How is the defect surgically repaired? The surgical repair of myeloschisis follows the principles of open spinal dysraphism closure, aiming to preserve functional neural tissue, prevent infection/CSF leak, and eliminate tethering. However, because the placode is wide and flat rather than sac-like, reconstruction requires precise micro-dissection and layered closure. Surgical steps include: Microdissection of the Placode (Defining the Junction): Under the operating microscope, the junction between the non-neural surface epithelium and the neural placode is identified. The epithelium is sharply dissected off the placode edge to prevent epidermal inclusion cysts (dermoids) down the road. Re-tubularization of the Placode: The flat, open placode is gently folded inward and its lateral edges are approximated using fine (6-0 or 7-0) monofilament sutures. Re-creating a neural tube restores central canal geometry and minimizes future spinal cord tethering to surrounding tissue. Watertight Dural Closure: The dural edges—found tethered laterally along the margins of the bony defect are sharply mobilized. A watertight, non-constricting duraplasty is performed over the placode (using autologous fascia or dural matrix graft if primary dural edges do not meet). Myofascial Flap Reconstruction: The paraspinous muscular fascia is incised laterally and mobilized medially over the dural closure to create a strong, secondary protective tissue barrier. Tension-Free Skin Closure: The surrounding skin and subcutaneous tissue are extensively undermined in the subgaleal-equivalent plane. A robust, multi-layered skin closure is achieved. For very large defects, plastic surgical techniques (such as rotational flaps or relaxing incision maneuvers) are utilized to avoid tension and wound dehiscence. Q. What is the prognosis in myeloschisis? Prognosis is generally poorer than in typical MMC because of the extent of neurulation failure. Lower-limb paralysis and neurogenic bladder are expected. Hydrocephalus is common and may require shunting. Long-term complications include tethered cord, scoliosis, and urological deterioration.

Meningiomas Tentorial Meningioma The session focuses on how to understand tentorial meningioma locations, surgical corridors, operative planning, and key anatomical landmarks that guide safe tumor removal. The goal is to make complex skull base anatomy clear, structured, and easy to remember for neurosurgery residents and practicing neurosurgeons. Foramen Magnum Meningioma In this episode of Mefty Made Easy, we simplify the concept of foramen magnum meningiomas, focusing on the key anatomical relationships, tumor classification, and surgical considerations that every neurosurgeon should understand. Using imaging and anatomical concepts, this session explains the location of foramen magnum meningiomas, their relationship to the brainstem, vertebral artery, lower cranial nerves, and the surgical corridors used for safe tumor removal. Transclival Approach & Foramen Magnum Meningioma In this episode of Mefty Made Easy, we explore the transclival approach to foramen magnum meningiomas and its role in skull base surgery. This session explains the endoscopic endonasal corridor to the clivus, the anatomical relationships of the brainstem, vertebral artery, and lower cranial nerves, and how these structures influence surgical planning. Olfactory Groove Meningioma In this episode of Mefty Made Easy, we simplify the concept of olfactory groove meningiomas, focusing on their surgical anatomy, clinical presentation, radiologic features, and operative approaches. These tumors arise from the anterior cranial fossa along the cribriform plate and planum sphenoidale, often presenting with anosmia, frontal lobe symptoms, and visual disturbances. Clinoidal Meningioma & Surgical Anatomy | Part 1 This video focuses on the core anatomical concepts and classification systems essential for understanding clinoidal meningiomas. Complex skull base anatomy is broken down into clear, exam-oriented explanations, with emphasis on the MEFTY classification and its surgical relevance. Clinoidal Meningioma | Part 2 This video builds on foundational anatomy and classification to cover the real-world clinical and operative aspects of clinoidal meningiomas. The topic is simplified into clear, exam-oriented concepts, helping you connect anatomy with surgical decision-making. Sphenoid Wing Meningioma | Part 1 Master Sphenoid Wing Meningioma in this high-yield session from the MEFTY Made Easy Series, designed for neurosurgery residents and exam candidates. This video simplifies the complex skull base anatomy and surgical considerations of sphenoid wing meningiomas into clear, exam-oriented concepts. With a focus on anatomical relationships and operative thinking, this session builds a strong foundation for both viva preparation and clinical application. Sphenoid Wing Meningioma | Part 2 In this video, we simplify the anatomy of sphenoid wing meningioma, focusing on key surgical and anatomical concepts essential for neurosurgery residents and trainees. We cover: Sphenoid wing anatomy and surgical relevance Relationship to critical neurovascular structures Key concepts for operative planning Practical insights for real-world neurosurgical decision-making Parasagittal Meningioma | Part 1 In Part 1 of this Parasagittal Meningioma series, we focus on the critical microsurgical anatomy that determines safe operative planning and execution. This session emphasizes the anatomy and surgical significance of the superior sagittal sinus, cortical draining veins, bridging veins, falx cerebri, and venous collateral pathways. Understanding these structures is essential for selecting the correct approach, minimizing venous injury, and avoiding catastrophic postoperative complications such as venous infarction and brain swelling. Parasagittal Meningioma | Part 2 In Part 2 of this Parasagittal Meningioma series, we focus on the classification, clinical presentation, and radiologic evaluation of parasagittal meningiomas. This session discusses how tumor location along the superior sagittal sinus influences symptoms, venous involvement, surgical complexity, and operative planning. We also review the key MRI and CT findings that help differentiate parasagittal meningiomas from other extra-axial lesions. Surgical Management of Parasagittal Meningioma In this video, we discuss the surgical management of parasagittal meningiomas with a focus on operative planning, venous preservation, and microsurgical strategy. Parasagittal meningiomas present unique challenges because of their relationship with the superior sagittal sinus and cortical draining veins. This session emphasizes how surgical anatomy influences positioning, craniotomy design, dural opening, tumor devascularization, sinus management, and safe resection techniques. Falcine Meningioma Part 1 | Surgical Anatomy, Classification and Venous Relationships In Part 1 of this Falcine Meningioma series, we discuss the essential surgical anatomy, classification, and venous relationships that form the foundation for safe operative planning. Falcine meningiomas present unique microsurgical challenges because of their deep interhemispheric location and close relationship to the falx cerebri, superior sagittal sinus, cortical draining veins, pericallosal arteries, and medial frontal/parietal cortex. Falcine Meningioma Part 2 | Clinical Presentation, Classification, & MRI Findings In Part 2 of this Falcine Meningioma series, we discuss the clinical presentation, radiologic evaluation, classification systems, surgical principles, and important operative adjuncts relevant to falcine meningioma surgery. This session focuses on how tumor location within the falx influences symptoms, venous anatomy, surgical complexity, and operative planning. We also review the conventional classification systems as well as the Das et al. classification and their relevance in surgical decision-making. Falcine Meningioma Surgical Management | Interhemispheric Approach and Microsurgical Strategy In this video, we discuss the surgical management of falcine meningiomas with a focus on interhemispheric microsurgical anatomy, operative strategy, and safe tumor resection principles. Falcine meningiomas are challenging lesions because of their deep location and close relationship to the falx cerebri, superior sagittal sinus, cortical bridging veins, and pericallosal arteries. This session emphasizes how surgical anatomy directly influences positioning, craniotomy planning, venous preservation, tumor devascularization, and operative decision-making. Falcotentorial Meningioma Part 1 | Surgical Anatomy and Deep Venous Relationships & Classification In Part 1 of this Falcotentorial Meningioma series, we discuss the complex surgical anatomy and deep venous relationships that are critical for safe operative planning and microsurgical resection. Falcotentorial meningiomas are rare and technically demanding lesions located at the junction of the falx cerebri and tentorium cerebelli, closely related to the deep venous system, vein of Galen, straight sinus, internal cerebral veins, and pineal region anatomy. This session focuses on understanding the microsurgical anatomy that determines surgical approach selection, venous preservation, operative corridors, and complication avoidance. Falcotentorial Meningioma Part 2 | Presentation, Approaches, Deep Venous Anatomy & Operative Nuances Falcotentorial meningiomas remain among the most technically demanding intracranial tumors because of their deep location and intimate relationship with the vein of Galen complex, straight sinus, internal cerebral veins, basal veins of Rosenthal, and the tentorial incisura. In Part 2 of this Falcotentorial Meningioma series, we focus on the surgical management of these challenging lesions. Through a practical neurosurgical perspective, we discuss operative planning, patient positioning, surgical corridors, deep venous anatomy, tumor devascularization, microsurgical dissection techniques, and strategies for preserving critical venous structures. Occipital Transtentorial Approach Explained | Surgical Anatomy, Indications, Deep Venous System The Occipital Transtentorial Approach (OTA) is one of the most versatile and elegant microsurgical corridors for accessing lesions of the pineal region, posterior third ventricle, falcotentorial junction, tentorial incisura, and deep midline structures. In this episode of The Surgical Blueprint, we simplify the anatomy, indications, surgical planning, patient positioning, tentorial opening, deep venous anatomy, and technical nuances of the occipital transtentorial approach. Sphenoid Wing Meningioma | Part 2 In this video, we simplify the anatomy of sphenoid wing meningioma, focusing on key surgical and anatomical concepts essential for neurosurgery residents and trainees. We cover: Sphenoid wing anatomy and surgical relevance Relationship to critical neurovascular structures Key concepts for operative planning Practical insights for real-world neurosurgical decision-making

Overview: Pituitary Adenoma & EETA Pituitary Adenoma | Part 1 This is Part 1 of the series, focusing on the fundamentals of pituitary adenomas, including classification, clinical presentation, endocrinology, and imaging essentials. The topic is simplified into exam-oriented, clinically relevant concepts for quick understanding and retention. Pituitary Adenoma & Endonasal Transsphenoidal Approach | Part 2 This video focuses on the surgical approach and relevant anatomy of pituitary adenomas, presented in a simplified, exam-oriented format. You will learn: Indications for surgical management of pituitary adenoma Key sellar and parasellar anatomy relevant to the transsphenoidal route Overview of the endonasal transsphenoidal approach Important surgical concepts for safe and effective tumor access

Coming Soon.

Os Odontoideum Os odontoideum is a condition characterized by a smooth, well-corticated, round or oval ossicle separated from the body of the axis by a gap, representing a detached odontoid process. It is considered either a congenital segmentation anomaly or an acquired post-traumatic non-union of the odontoid synchondrosis. Embryology and Pathogenesis: The odontoid process develops from multiple ossification centers; one for the basal (body) portion and another for the apical portion (ossiculum terminale). Fusion with the C2 body occurs through the dentocentral synchondrosis (also known as the subdental synchondrosis) during early childhood. At birth, this synchondrosis separates the dens from the C2 body. It normally begins to fuse around 3 years of age and is completely fused by 5–6 years. Persistence beyond 7 years is considered abnormal. Failure of this fusion (congenital) or post-traumatic separation before fusion (acquired) results in os odontoideum. Hence, os odontoideum represents either a developmental anomaly of the dens or the sequela of early childhood fracture before synchondrosis closure. Classification: 1. Orthotopic type – The ossicle lies in the normal anatomic position, in line with the anterior arch of the atlas. 2. Dystopic type – The ossicle is displaced upward toward the foramen magnum, sometimes even articulating with the clivus. Both forms may be associated with atlantoaxial instability. Associated Conditions: Os odontoideum frequently coexists with congenital and craniovertebral anomalies such as Chiari I malformation, basilar invagination, platybasia, occipitalization of the atlas, and Klippel–Feil syndrome. These associations support the congenital or developmental theory in many cases. Clinical Presentation: Patients may be asymptomatic or present with symptoms caused by instability at the atlantoaxial junction or direct cord compression, including neck pain or stiffness, restricted cervical motion, torticollis, transient quadriparesis after minor trauma, or progressive myelopathy. Sudden neurological deterioration after trivial trauma is a known presentation. Radiologic Features: Plain radiographs show a well-corticated, oval or round ossicle separated from the axis body by a distinct gap. Dynamic flexion–extension X-rays demonstrate atlantoaxial instability. CT defines the corticated ossicle, the degree of separation, and bone remodeling at the base of C2. MRI shows spinal cord compression, myelomalacia, or associated anomalies such as Chiari I malformation or basilar impression. Management: Asymptomatic and stable lesions are managed conservatively with follow-up. Symptomatic or unstable cases require surgical stabilization. The standard treatment is posterior C1–C2 fixation (Goel–Harms or transarticular screws). Occipitocervical fusion is preferred if posterior elements are dysplastic or instability extends to the occiput. Complications of C1–C2 Fixation in a Young Patient: Intraoperative and immediate complications: vertebral artery injury, dural tear and CSF leak, neural injury (C2 root or spinal cord), hardware malposition or loosening, and wound infection or hematoma. Delayed complications: pseudoarthrosis or nonunion, loss of fixation, adjacent segment degeneration, growth disturbance, and loss of neck mobility due to fusion. Degrees of Movement Lost After C1–C2 Fusion: The atlantoaxial joint contributes approximately 50–60% of cervical rotation and a smaller component of flexion–extension. Rotation: each side provides around 40°–45°, so total rotation (~80–90°) is reduced by about half after fusion. Flexion–Extension: contributes 10°–15°, so mild reduction in nodding movement occurs. Lateral bending: minimal (<5°). After fixation, about 50% of rotational mobility is lost but flexion, extension, and lateral bending are largely preserved, allowing normal function through compensation by subaxial cervical segments. Differentiation Between Os Odontoideum and Odontoid Fracture (Type II): Os odontoideum shows smooth, corticated margins, a smaller rounded ossicle, and chronic bone remodeling, while type II odontoid fracture shows sharp, irregular non-corticated edges, normal-sized dens, and soft tissue swelling. Radiologic differences: Os odontoideum: wide, uniform gap (2–4 mm), hypertrophied anterior arch of atlas, smooth concave upper C2 surface, no marrow edema. Fracture: irregular gap, sharp surfaces, prevertebral swelling, marrow edema on MRI. Associated anomalies such as Chiari I malformation or basilar invagination further support os odontoideum, while fracture is purely traumatic. Recalls: Dentocentral fusion normally completes by 5–6 years. Os odontoideum: detached corticated ossicle, chronic pseudoarthrosis. Two types: orthotopic and dystopic. Associations: Chiari I, basilar invagination, Klippel–Feil. Management: stabilize if unstable or symptomatic. C1–C2 fusion results in ~50% loss of rotation with minimal effect on flexion/extension. Differentiation from acute fracture: corticated margins, absence of marrow edema, remodeling of C2 body.

Astrocytomas & Oligodendrogliomas Diffuse gliomas represent a spectrum of infiltrative tumors with distinct molecular and clinical behavior. Understanding classification and surgical strategy is key to management. Glioblastoma Part 1 of the Glioblastoma series focuses on diagnostic foundations, including classification, radiologic patterns, common imaging pitfalls, wounded glioma syndrome, and histologic subtypes, discussed through real clinical cases. A major emphasis of this session is understanding why radiology alone can be misleading, how glioblastoma can mimic other pathologies, and how neurosurgeons integrate imaging with clinical reasoning in day-to-day practice. Part 2 of the Glioblastoma series builds on the diagnostic foundations discussed earlier and focuses on prognostic assessment, treatment strategy, and evolving concepts in glioblastoma management, discussed through real clinical cases. Key areas of discussion include radiomics and advanced imaging features, how prognostic information is derived from clinical and radiologic variables, and how these factors influence surgical planning, extent of resection, and adjuvant treatment decisions in routine practice.

Cerebral Abscess A cerebral abscess is a localized, focal, suppurative infection within the brain parenchyma that begins as an area of cerebritis and evolves into a collection of pus surrounded by a capsule. It represents the host’s attempt to contain infection. Q. What are the stages of evolution of a brain abscess? 1. Early cerebritis (1–3 days): Perivascular inflammation and necrosis, no capsule. 2. Late cerebritis (4–9 days): Expanding necrosis, peripheral fibroblast proliferation. 3. Early capsule (10–13 days): Capsule formation begins with fibroblast collagen deposition. 4. Late capsule (≥14 days): Thick collagen capsule surrounded by gliosis and reduced edema. Steroids slow capsule formation and should be avoided unless there is significant mass effect. Q. What are the routes of spread of infection? Which is most common? 1. Hematogenous spread (most common): From lung abscess, bronchiectasis, empyema, endocarditis, skin sepsis, pelvic infection, or cyanotic congenital heart disease. In congenital heart disease, right-to-left shunts bypass pulmonary filtration, allowing septic emboli to reach the brain. Usually results in multiple abscesses at the gray–white junction. 2. Contiguous spread (30–40 %): From sinusitis (especially frontal and sphenoid), otitis media, mastoiditis, or dental sepsis. Typically causes solitary abscess in adjacent lobe. 3. Direct inoculation: Post-neurosurgical procedures, compound fractures, or penetrating trauma. 4. Cryptogenic: No identifiable source (10–15 %). Q. What are the common causative organisms? Most common overall: Streptococcus species (esp. S. milleri group). Polymicrobial: Found in up to 60 % of cases. Anaerobes: Bacteroides, Peptostreptococcus, Fusobacterium. Gram-negative bacilli: Proteus, E. coli, Klebsiella, Pseudomonas. Neurosurgical procedures: Staphylococcus aureus, Staphylococcus epidermidis, Pseudomonas aeruginosa. Penetrating trauma: Clostridium, Staphylococcus aureus, Pseudomonas. In AIDS / immunocompromised: Nocardia, Toxoplasma gondii, Aspergillus, Candida, Mucor. Q. What are the common locations and their sources? Temporal lobe and cerebellum: Otitis media, mastoiditis Frontal lobe: Frontal or sphenoid sinusitis, dental sepsis Parietal lobe: Postoperative or post-traumatic Occipital lobe: Chronic pulmonary sepsis, cyanotic heart disease Multiple abscesses: Bacteremia or endocarditis Q. What investigations will you perform? CBC: Leukocytosis in ~60%. ESR / CRP: CRP elevation in nearly all; sensitivity ~97%, specificity ~80%. Blood cultures: Positive in 10–20%. CT brain with contrast: - Early cerebritis: Poorly defined hypodensity. - Mature abscess: Ring-enhancing lesion with smooth inner margin, hypodense center, vasogenic edema. - Double ring sign characteristic (outer capsule + inner granulation). MRI: - T1: Central hypointensity with enhancing capsule. - T2: Central hyperintensity with hypointense rim. - DWI: Restricted diffusion in abscess cavity (distinguishes from tumor necrosis). Leukocyte (HMPAO) scan: Localizes active suppuration and differentiates abscess from tumor or sterile cystic lesions. (Most accurate) MR spectroscopy: Shows lactate, acetate, and succinate peaks (unique to bacterial metabolism). Aspiration for culture and sensitivity is the diagnostic gold standard. Q. What are the imaging features distinguishing late cerebritis from early capsule stage? In late cerebritis, rim enhancement appears irregular and incomplete. In early capsule stage, the rim becomes smooth and complete with reduced central diffusion restriction. With steroid therapy, enhancement and perilesional edema may prematurely decline, making differentiation challenging. Q. What are the differential diagnoses of a ring-enhancing lesion? High-grade glioma, metastasis, tuberculoma, toxoplasmosis, subacute infarct, demyelination, or resolving hematoma. Q. How will you manage a case of cerebral abscess? 1. Medical management (selected cases only): Indications: - Abscess < 3 cm in diameter - No significant mass effect or midline shift - Glasgow Coma Scale > 12 - Etiology and organism known - Abscess in deep or eloquent area (thalamus, brainstem) not surgically accessible - Early cerebritis on imaging - Multiple small abscesses without mass effect - Post-surgical patients with sterile collections - Concomitant meningitis or ependymitis (surgery contraindicated until sterilization) Regimen: - Ceftriaxone 2 g IV q12h or Cefotaxime 2 g IV q6h - Metronidazole 500 mg IV q6h - Vancomycin 15 mg/kg IV q8–12h Duration: Minimum 6–8 weeks IV, continued until contrast enhancement resolves. Endpoint: Disappearance of enhancement and edema on serial MRI. Monitoring: ESR, CRP, weekly CT/MRI. Steroids: Avoid unless mass effect is severe; they delay capsule formation and antibiotic penetration. Q. What are the indications for surgical treatment? 1. Size > 3 cm 2. Neurological deterioration or low GCS 3. Mass effect or midline shift 4. Diagnostic uncertainty (to exclude tumor) 5. Failure of medical therapy after 2 weeks 6. Multiple abscesses with one dominant lesion 7. Superficial or traumatic abscess near dura 8. Posterior fossa abscess 9. Gas-containing abscess (suggests anaerobes) 10. Impending rupture into ventricles Contraindications: Concomitant meningitis or ependymitis until infection controlled Q. What are the surgical options? Needle aspiration (stereotactic or open) is the mainstay for most cases; allows decompression and culture with minimal morbidity. Excision (en bloc removal): Reserved for encapsulated abscesses near cortical surface, recurrent abscess, fungal or foreign-body-related lesions. Multiple abscesses: Target the dominant or largest lesion first, followed by staged aspirations. Penetrating trauma abscess: Debridement of necrotic brain and removal of foreign body, followed by prolonged antibiotics. Q. What are the key points in postoperative management? Serial CT or MRI every 48–72 h after aspiration. Continue IV antibiotics for minimum 8 weeks or longer until full radiologic resolution. Continue AEDs for 6 months (seizure prophylaxis). Manage ICP; if refractory, consider decompressive craniectomy. Treat and eradicate the primary focus (sinus, ear, dental, or cardiac source). Q. What are the complications of cerebral abscess? Rupture into ventricles (fatal in 80 %). Subdural or epidural empyema. Hydrocephalus. Seizures and focal deficits. Recurrence, especially with incomplete capsule removal or immunosuppression. Q. What is the prognosis? Mortality 10–20 %, prognosis is best with early diagnosis and adequate therapy. Neurological sequelae (hemiparesis, epilepsy) in up to 50 %. Fungal and multiple abscesses have poorer prognosis.

Neurofibromatosis Type 1, Type 2, and Schwannomatosis Q. What is Neurofibromatosis? Neurofibromatosis refers to a group of autosomal dominant neurocutaneous disorders characterized by the formation of nerve sheath tumors, skin pigmentation abnormalities, and systemic manifestations involving multiple organ systems. The three major recognized forms are Neurofibromatosis Type 1 (NF1), Neurofibromatosis Type 2 (NF2), and Schwannomatosis, all part of the neurofibromatosis-schwannomatosis spectrum. Neurofibromatosis Type 1 (NF1) Q. What is the genetic basis of NF1? NF1 results from mutations in the NF1 gene on chromosome 17q11.2, which encodes neurofibromin, a tumor suppressor protein that negatively regulates RAS signaling. Loss of neurofibromin leads to excessive RAS/MAPK pathway activation and uncontrolled Schwann cell proliferation. Q. What is the inheritance pattern? NF1 is autosomal dominant with variable expressivity and complete penetrance by adulthood. Around 50% of cases arise from de novo mutations. Q. What are the updated 2021 International Diagnostic Criteria for Neurofibromatosis Type 1 (NF1)? Diagnosis requires two or more of the following: 1. Six or more café-au-lait macules (>5 mm prepubertal, >15 mm postpubertal). 2. Two or more neurofibromas of any type, or one plexiform neurofibroma. 3. Axillary or inguinal freckling (Crowe sign). 4. Optic pathway glioma. 5. Two or more Lisch nodules (iris hamartomas), OR two or more choroidal abnormalities (bright patch lesions identified by near-infrared reflectance imaging / optical coherence tomography). 6. Distinctive osseous lesion such as sphenoid wing dysplasia, anterolateral bowing of the tibia, or pseudarthrosis of a long bone. 7. A heterozygous pathogenic NF1 gene variant with a variant allele fraction of 50% in normal tissue. 8. A parent who meets the diagnostic criteria for NF1 specified above. (Only a biological parent who officially meets the diagnostic criteria qualifies as a positive family history. Siblings and children no longer satisfy this criterion on their own, even if they have confirmed cases of NF1.) Q. What are the additional supportive (nonessential) features of NF1? Macrocephaly, short stature, and learning disabilities or ADHD. Seizures, developmental delay, or autism spectrum traits. Scoliosis, vertebral scalloping, long bone bowing, and tibial dysplasia. Vascular lesions (e.g., renal artery stenosis, moyamoya-like disease). Endocrine abnormalities, including precocious puberty (optic-hypothalamic glioma). Pheochromocytoma, GISTs, glomus tumors, and juvenile xanthogranulomas. Choroidal hamartomas visible on near-infrared OCT. Elephantiasis neuromatosa from plexiform neurofibroma overgrowth. Q. What are the clinical features of NF1? Cutaneous: café-au-lait macules, axillary/inguinal freckles, dermal and plexiform neurofibromas. Ophthalmic: Lisch nodules, optic pathway glioma. Neurologic: learning disability, ADHD, seizures, headaches. Skeletal: scoliosis, bone dysplasia. Tumors: MPNST, astrocytoma, pheochromocytoma. Q. What are the radiologic findings? MRI brain may show optic pathway glioma and T2 hyperintense white matter lesions (“unidentified bright objects”). Plexiform neurofibromas appear as T2 target sign lesions. Q. How is NF1 managed? Observation for asymptomatic lesions. Surgical excision for symptomatic or disfiguring neurofibromas. Optic gliomas: observe unless progressive visual loss. When treatment is required for progressive vision loss or imaging advancement, chemotherapy (e.g., carboplatin/vincristine or BRAF/MEK inhibitors) is first-line; radiation is strictly avoided due to the high risk of secondary malignancies and moyamoya syndrome. Screening: annual BP, ophthalmology, and neuro exam; MRI only if symptomatic. MPNST suspicion: rapid growth, pain, or heterogeneity on MRI → biopsy. Q. What is the prognosis? Most live normal lifespans; risk of malignant transformation (MPNST) and vascular complications determine prognosis. Neurofibromatosis Type 2 (NF2) Q. What is the genetic basis of NF2? NF2 is caused by mutations in the NF2 gene on chromosome 22q12, encoding merlin (schwannomin), a tumor suppressor that regulates cell–cell contact inhibition. Loss of merlin leads to Schwann cell overgrowth and meningeal proliferation. Q. What is the inheritance pattern? NF2 is autosomal dominant with variable expression and near-complete penetrance by age 60. Around 50% are de novo mutations, and one-third of those are mosaic. Q. What are the diagnostic criteria for NF2-related schwannomatosis (updated 2022)? Diagnosis can be made by: 1. Bilateral vestibular schwannomas, or 2. A first-degree relative with NF2-related schwannomatosis plus either - unilateral vestibular schwannoma, or - any two of: meningioma, schwannoma, glioma, neurofibroma, or juvenile cataract. 3. NF2 pathogenic variant in blood or tumor, with compatible clinical features. Q. What are supportive clinical features of NF2? Bilateral vestibular schwannomas (pathognomonic). Multiple meningiomas (intracranial and spinal). Spinal ependymomas and schwannomas. Ocular: posterior subcapsular cataract, epiretinal membranes, retinal hamartomas. Cutaneous: plaque-like or subcutaneous schwannomas (no café-au-lait spots). Cranial neuropathies and hearing loss as early symptoms. Family history of early-onset hearing loss or CNS tumors. Q. What is the typical age of presentation? Adolescence or early adulthood, though pediatric onset may occur in mosaic NF2. Q. What are the imaging findings? MRI Brain/IAC: bilateral vestibular schwannomas, multiple meningiomas. MRI spine: intradural extramedullary schwannomas, ependymomas, or meningiomas. Q. How is NF2 managed? MRI surveillance (brain and spine every 12–24 months). Microsurgery or radiosurgery for symptomatic tumors. Bevacizumab for progressive vestibular schwannomas to reduce growth and improve hearing. Rehabilitation with cochlear or brainstem implants for hearing loss. Genetic counseling for family. Q. What is the prognosis? Progressive and multisystemic; median life expectancy around 60 years. Morbidity arises from bilateral hearing loss and brainstem compression. Schwannomatosis Q. What is schwannomatosis? Schwannomatosis is a rare tumor predisposition syndrome characterized by multiple non-vestibular schwannomas without bilateral vestibular schwannomas. It is now considered part of the NF2-related schwannomatosis spectrum. Q. What is the genetic basis? Three defined molecular subtypes: 1. NF2-related schwannomatosis – NF2 gene mutation (chromosome 22q12). 2. SMARCB1-related schwannomatosis – SMARCB1 mutation (chromosome 22q11.23). 3. LZTR1-related schwannomatosis – LZTR1 mutation (chromosome 22q11.23). Tumorigenesis follows a four-hit, three-step model: biallelic loss of both NF2 and one modifier gene (SMARCB1 or LZTR1) in the same cell. Q. What is the inheritance pattern? Autosomal dominant with incomplete penetrance and variable expressivity. Many cases are sporadic. Q. What are the diagnostic criteria (2022 update)? Clinical diagnosis: - Two or more non-intradermal schwannomas confirmed histologically. - No bilateral vestibular schwannomas on MRI. - No constitutional NF2 mutation or first-degree relative with NF2. Molecular diagnosis: - Pathogenic variant in SMARCB1, LZTR1, or NF2, in germline or mosaic form, without bilateral vestibular involvement. Q. What are the clinical features? Chronic or paroxysmal pain (hallmark symptom). Palpable nerve masses along peripheral or spinal nerves. No vestibular or hearing symptoms. Minimal skin lesions, no café-au-lait spots or Lisch nodules. May have mononeuropathies or focal weakness due to nerve compression. Q. What are the radiological features? MRI: multiple enhancing schwannomas along peripheral or spinal nerves, no vestibular schwannomas. Diffusion and contrast help differentiate from meningiomas or neurofibromas. Q. What are the histopathological findings? Typical schwannoma pattern: - Antoni A and Antoni B areas. - Verocay bodies in Antoni A. - Strong S-100 positivity. - No entrapped axons (unlike neurofibroma). Q. What are the differences among genetic subtypes? SMARCB1-related: early onset, spinal schwannomas, occasional meningiomas. LZTR1-related: peripheral nerve tumors, occasional unilateral vestibular schwannoma. NF2-related: mosaic or milder NF2 phenotype. Q. How is schwannomatosis managed? Surgical resection of symptomatic schwannomas. Pain control with neuropathic agents and nerve blocks. MRI surveillance every 2–3 years. Genetic counseling for family. No established drug therapy; bevacizumab is ineffective except in NF2-related cases. Q. What is the prognosis? Excellent life expectancy; main morbidity is chronic neuropathic pain and recurrent surgeries. Histologic Discussion: Schwannoma vs Neurofibroma Q. How do schwannoma and neurofibroma differ? Schwannoma: encapsulated, eccentric to nerve, purely Schwann cells, Antoni A/B areas, Verocay bodies, strong S-100, no axons, enucleable, rare malignancy. Neurofibroma: unencapsulated, intraneural, mixed cell types with axons inside, patchy S-100, CD34 positive stroma, “shredded carrot” collagen, plexiform type has MPNST risk. Target sign on MRI typical for neurofibroma; heterogeneous appearance for schwannoma. Q. What are Antoni A and Antoni B areas, and Verocay bodies? Antoni A areas are hypercellular and organized with nuclear palisading. Antoni B areas are hypocellular, myxoid, and loosely arranged. Verocay bodies are rows of palisaded nuclei separated by acellular eosinophilic zones of Schwann cell processes, pathognomonic for schwannoma. Q. What is segmental or mosaic NF? A postzygotic mutation causing localized disease limited to one body segment; germline mosaicism can still transmit generalized NF to offspring. Q. What is plexiform neurofibroma and why is it significant? Pathognomonic of NF1, involving multiple fascicles (“bag of worms”). Carries 10–15% risk of malignant transformation to MPNST. Q. What is MPNST? A high-grade sarcoma arising from plexiform neurofibroma or peripheral nerve sheath, characterized by pain, rapid growth, and heterogeneous MRI appearance. Genetic mechanisms of tumorigenesis: Both NF1 and NF2 follow the two-hit tumor suppressor model; loss of both alleles (somatic and germline) causes tumor formation. NF1: RAS pathway dysregulation. NF2: loss of contact inhibition via merlin deficiency. Follow-up protocols: NF1 – annual BP, neuro and eye exams, MRI if symptomatic. NF2 – MRI brain/IAC annually, spine every 2–3 years, audiology yearly. Schwannomatosis – MRI every 2–3 years, pain and nerve function monitoring. Final recall summary: NF1 = Peripheral + Pigmentary. NF2 = Central + Vestibular. Schwannomatosis = Multiple Painful Schwannomas, No Vestibular Involvement.

Coming Soon.